Galderma (GALD) Earnings: FY Net Sales Growth Forecast Revised to 8.8%-9.5%

Galderma on Smartkarma

Analyst coverage on Galderma by Dimitris Ioannidis on Smartkarma reveals that Galderma (GALD SW) is poised to make a significant impact on the Global and Swiss Indices in the upcoming reviews scheduled for August and September 2024. Following its $17 billion IPO in March 2024, Galderma is expected to be one of the largest additions to these indices. The company is projected to be included in the second Global Index at the September 2024 review, with an estimated demand of approximately $162 million and 5.0 ADV. Additionally, the IPO lock-up expiry in December 2024 is anticipated to generate an additional demand of around $42 million and 1.3 ADV.

A look at Galderma Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Galderma Group AG, a leading dermatology company, shows a promising long-term outlook based on Smartkarma Smart Scores analysis. With a strong emphasis on growth and momentum, Galderma scored a solid 5 in Growth and an impressive 4 in Momentum. This indicates a positive trajectory for the company in terms of expanding its market presence and performance over time. Additionally, Galderma received decent scores in Value and Resilience, reflecting a stable financial standing and ability to weather economic uncertainties. Despite a lower score in Dividend, the company’s overall outlook appears favorable, especially with its focus on delivering science-based dermatological products and services globally.

Galderma‘s strategic positioning in the dermatology market, offering a diverse range of brands and services from injectable aesthetics to therapeutic dermatology, underscores its commitment to addressing various skin-related needs. Serving customers worldwide, the company’s emphasis on innovation and quality aligns well with its high scores in Growth and Momentum. As Galderma continues to leverage its strong market presence and research-driven approach, the company is poised to capitalize on opportunities for growth and sustained performance in the dermatology sector.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma